Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk for Genetic Medicines
Sep 18, 2024•over 1 year ago
Contract Type
partnership
Description
NanoVation Therapeutics has announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. Under the agreement, they will collaborate on developing base-editing therapies for rare genetic diseases and future targets for cardiometabolic and rare diseases.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months